Prognose

Das durchschnittliche Kursziel der Analysten beträgt +44,20€(+8,63%). Der Median liegt bei +42,80€(+5,19%).

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a.» Mehr auf businesswire.com
Qiagen N.V. - Shareholder/Analyst Call
Presenter SpeechLawrence Rosen (Executives)Ladies and gentlemen, let me welcome you to this Annual General Meeting of QIAGEN. My name is Larry Rosen, and I serve as Chairman of the Supervisory Board.B» Mehr auf marketscreener.com
QGEN vs. EXAS: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?» Mehr auf zacks.com

Im letzten Quartal hatte Qiagen NV einen Umsatz von 446,89 Mio€ und ein Nettoeinkommen von 83,89 Mio€